director photo

Prof. Denys

Damiaan Denys
Department of Psychiatry (PA.2-179)
Academic Medical Center
University of Amsterdam
PO Box 75867
1070 AW Amsterdam
Tel. +31-20-8913899
Fax +31-20-8913898
Email: d.denys@amc.nl
Websites:
http://www.amcpsychiatrie.nl/
http://www.nin.knaw.nl/

Education
2000-2004 UMC Utrecht Psychiatry PhD
1996-2002 KUL University Leuven Psychiatry Residency
1989-1996 KUL University Leuven Medicine Master (MD)
1984-1989 KUL University Leuven Philosophy Master (MSc)

Academic and medical professional experience
2009- : Team leader at the Institute for Neuroscience (NIN), an institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands
2007- : Chair of the department of Psychiatry at the Academic Medical Centre (AMC) Amsterdam
2007- : Professor of Psychiatry (Kernhoogleraar) at the University of Amsterdam (UVA)
2004-2007: Chief section anxiety disorders at the UMC Utrecht
2004: PhD Cum Laude, “On certainty: studies in obsessive compulsive disorder”
2002-2004: Staff member section anxiety disorders at the UMC Utrecht
2002: Registration as Psychiatrist
2000-2004: PhD student at the department of psychiatry UMC Utrecht
1996-2002: Residency in psychiatry at the Universities in Leuven and Utrecht
1996: Registration as Medical Doctor
1989: MSc Philosophy, “The personality concept in “Le Cas Aimee” from the earlier works of Jacques Lacan”

Administrative responsibilities
2010-Member of the Anxiety Disorders Research Network (ADRN)
2010-Board member of the International College of Obsessive Compulsive Spectrum Disorders (ICOCS)
2010- Evaluation Committee of the French National Research Agency (ANR) for neurosciences
2009-Kenniskamer “Human Enhancement”
2009-Scientific Board Nederlandse Hersenbank
2009-Evaluation Committee of the Dutch National Research Agency (NWO) for clinical medical research
2009-Director of the International OCD spectrum disorders consortium Advisory Board CSCA UVA
2009-Member of the scientific advisory committee of the ECNP
2008-Advisor Workgroup Anxiety disorders DSMV committee
2008-Covenor and scientific advisory board IADS Member of the Collegium Internationale Neuropsycho-pharmacologicum (CINP)
2007-Board of Directors Spinozacentrum Amsterdam
2006-Member of Nederlandse Vereniging voor Psychiatrie (NVVP)
2006-Member of the International OCD genetics consortium
2006-Member of the European College of Neuropsychopharmacology (ECNP)
2006-Member of the International Society for Neuroscience (SFN)

Current research interest
Damiaan Denys conducts clinical and neurobiological research into anxiety and obsessive-compulsive disorders. His scientific research is characterized by a translational approach and makes use of phenomenology, pharmacotherapy, animal models, neuroimaging, and neurogenetics. In order to develop connections between psychiatry and the fundamental neurosciences, he employs a new approach, which instead of examining disorders concentrates on broader concepts such as compulsivity, reward learning, and fear conditioning across disorders. A particular focus of his research is the development of deep brain stimulation (DBS) for psychiatric disorders such as obsessive-compulsive disorder, depression and addiction.

Editorial responsibilities
2006- : Associate Editor, Philosophy, Ethics and Humanities in Medicine
2007- : Editorial board, Reviews on Clinical trials
Referee for Archives of General psychiatry, American journal of psychiatry, Biological psychiatry, Journal of clinical psychiatry, International clinical psychiatry, European Archives of Psychiatry and Neurosciences, Psychopharmacology, American Journal of Medical genetics

Grants and Honours
2009: “A double blind, placebo controlled study of agomelatine in obsessive- compulsive disorder” granted by Servier
2009: “NWO Hersenen & Cognitie – maatschappelijke innovatie in gezondheidszorg, educatie en veiligheid” financed by FES granted by NWO
2009: “Inhibition, impulsivity and compulsivity” UVA – CSCA
2009: “Deep Brain Stimulation in Chronic Treatment Refractory Drug Dependence: a Translational Study” granted by ZonMw in collaboration with Wim van den Brink
2008: "D-cycloserine enhancement of exposure and response prevention (ERP) therapy in OCD and panic with agoraphobia: a randomized controlled trial" granted by ZonMW Doelmatigheid, VEMI, in collaboration with Danielle Cath
2007: “Deep brain stimulation in major depressive disorder” granted by Medtronic in collaboration with Rick Schuurman
2006: “D-cycloserine and fear extinction in obsessive compulsive disorder”, NWO, Clinical fellow-program.
2006: “Memory uncertainty in obsessive compulsive disorder”, NWO, Open MAGW program in collaboration with Marcel van den Hout
2005: “Ramaer Medaille”, scholarly award of the Dutch Society of Psychiatry for outstanding clinical research in Psychiatry
2005: “11C Raclopride positron emission tomography (PET) of amphetamine induced dopamine release in Tourette’s syndrome and obsessive compulsive disorder” granted by the Tourette Syndrome Association in collaboration with Danielle Cath.
2005: “Deep brain stimulation in obsessive compulsive disorder” granted by Medtronic in collaboration with Andries Bosch
2005: “Deep brain stimulation in obsessive compulsive disorder”, NWO, VENI-program. CV Damiaan Denys October 2010 5
2005: “De Girard de Mielet van Coehoorn” medaille for Cum Laude PhD thesis, scientific award from the UMC Utrecht
2003: “A double blind, placebo controlled study of Quetiapine addition in 90 patients with obsessive-compulsive disorder” granted by Astra-Zeneca
2003: “A double blind, placebo controlled study of Quetiapine in 60 patients with social phobia” granted by Astra-Zeneca
2000: “A double blind, placebo controlled study of Quetiapine addition in 40 treatment refractory patients with obsessive-compulsive disorder” granted by Astra-Zeneca.
Journal Articles & Book Chapters
1.Denys D, Mantione M, Figee M, van den Munckhof P, Koerselman F, Westenberg H, Bosch A, Schuurman R. Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2010;67:1061-8.
2.Olff M, Langeland W, Witteveen A, Denys D. A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. CNS Spectr. 2010;15:522-30.
3.Schutters SI, Van Megen HJ, Van Veen JF, Denys DA, Westenberg HG. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2010;25:302-4.
4.Figee M, Mantione M, van den Munckhof P, Schuurman R, and Denys D. Targets for Deep Brain Stimulation in Obsessive-Compulsive Disorder. Psychiatr Ann. 2010;40:492-498.
5.Stein DJ, Fineberg NA, Bienvenu OJ, Denys D, Lochner C, Nestadt G, Leckman JF, Rauch SL, Phillips KA. Could OCD be classified as an anxiety disorder in DSM-V? Depress Anxiety. 2010;27:495-506.
6.Katerberg H, Cath DC, Denys D, et al. The role of the COMT Val(158)Met polymorphism in the phenotypic expression of obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2010; 153B:167-176.
7.Kas MJ, Gelegen C, van Nieuwerburgh F, Westenberg HG, Deforce D, Denys D. Compulsivity in mouse strains homologous with chromosomes 7p and 15q linked to obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:252-259.
8.Katerberg H, Delucchi KL, Stewart SE, et al. Symptom Dimensions in OCD: Item-Level Factor Analysis and Heritability Estimates. Behav Genet. 2010;40:505-517.
9.Leckman JF, Denys D, Simpson HB, et al. Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. Depress Anxiety. 2010;27:507-527.
10.Prins J, Denys DA, Westphal KG, et al. The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats. Eur J Pharmacol. 2010;633:55-61.
11.Mantione M, van de Brink W, Schuurman PR, Denys D. Smoking cessation and weight loss after chronic deep brain stimulation of the nucleus accumbens: therapeutic and research implications: case report. Neurosurgery. 2010;66:E218;
12.Fluitman S, Denys D, Vulink N, Schutters S, Heijnen C, Westenberg H. Lipopolysaccharide-induced cytokine production in obsessive-compulsive disorder and generalized social anxiety disorder. Psychiatry Res. 2010; 178:313-316.
13.Figee M, Booij J, Denys D. Molecular imaging of Obsessive compulsive disorder. Understandig Neuropsychiatric Disorders: Insights from Neuroimaging. 2010.
14.Stein DJ, Denys D. Recent advances in understanding and treating the anxiety disorders. Introduction. CNS Spectr. 2009;14:4.
15.Figee M, Denys D. New pharmacotherapeutic approaches to obsessive-compulsive disorder. CNS Spectr. 2009;14:13-23.
16.de Haan L, Dudek-Hodge C, Verhoeven Y, Denys D. Prevalence of psychotic disorders in patients with obsessive-compulsive disorder. CNS Spectr. 2009;14:415-417.
17.Stein DJ, Denys D. Deep brain stimulation in obsessive-compulsive disorder. Curr Psychiatry Rep. 2009;11:259-260.
18.van Dijk A, Klompmakers A, Denys D. The serotonergic system in obsessive compulsive disorders. In: Handbook of the behavioral neurobiology of serotonin . ; 2009.
19.Nieman DH, Rike WH, Becker HE, et al. Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. Int Clin Psychopharmacol. 2009;24:223-228.
20.Van Nieuwerburgh FC, Denys DA, Westenberg HG, Deforce DL. Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. Int J Psychiatry Clin Pract. 2009;13:345-348.
21.Vulink NC, Denys D, Fluitman SB, Meinardi JC, Westenberg HG. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry. 2009;70:1001-1008.
22.Van Megen H, Denys D. [Obsessive compulsive disorder]. In: Leerboek Psychiatrie. De Tijdstroom; 2009.
23.Denys D, Mantione M. Deep brain stimulation in obsessive-compulsive disorder. Prog Brain Res. 2009;175:419-427.
24.Stein DJ, Denys D, Gloster AT, et al. Obsessive-compulsive disorder: diagnostic and treatment issues. Psychiatr Clin North Am. 2009;32:665-685.
25.Stein DJ, Denys D, Gloster AT, et al. Obsessive--compulsive Disorder: Diagnostic and Treatment Issues. Psychiatric Clinics of North America. 2009;32:665-685.
26.de Bruijn C, Beun S, de Graaf R, Ten Have M, Denys D. Subthreshold symptoms and obsessive-compulsive disorder: evaluating the diagnostic threshold. Psychol Med. 2009:1-9.
27.Fluitman SB, Denys DA, Heijnen CJ, Westenberg HG. Disgust affects TNF-alpha, IL-6 and noradrenalin levels in patients with obsessive-compulsive disorder. Psychoneuroendocrinology. 2009.
28.Montagne B, de Geus F, Kessels RP, Denys D, de Haan EH, Westenberg HG. CV Damiaan Denys October 2010 7
Perception of facial expressions in obsessive-compulsive disorder: a dimensional approach. Eur Psychiatry. 2008;23:26-28.
29.van Dijk A, Klompmakers A, Denys D. Role of serotonin in obsessive-compulsive disorder. Future Neurol. 2008;3:589-603.
30.Vulink NC, Rosenberg A, Plooij JM, Koole R, Bergé SJ, Denys D. Body dysmorphic disorder screening in maxillofacial outpatients presenting for orthognathic surgery. Int J Oral Maxillofac Surg. 2008;37:985-991.
31.Denys D. [Deep brain stimulation in psychiatric disorders]. Ned Tijdschr Geneeskd. 2008;152:2330-2335.
32.Spitzer U, Denys D. Sich frei fühlen oder frei sein? Zur Psychologie und . Nervenheilkunde. 2008;9.
33.Mantione M, Denys D. [Deep Brain Stimulation & CBT: a winning team?]. Tijdschr Psychiatr. 2008;12:133-136.
34.Denys D, de Haan L. [25 years antipsychotics: back to the future?]. Tijdschr Psychiatr. 2008;50 Spec no.:105-109.
35.Denys D, Fineberg N, Carey PD, Stein DJ. Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry. 2007;61:412-414.
36.Westenberg HG, Fineberg NA, Denys D. Neurobiology of obsessive-compulsive disorder: serotonin and beyond. CNS Spectr. 2007;12:14-27.
37.van der Wee NJ, Ramsey NF, van Megen HJ, Denys D, Westenberg HG, Kahn RS. Spatial working memory in obsessive-compulsive disorder improves with clinical response: A functional MRI study. Eur Neuropsychopharmacol. 2007;17:16-23.
38.Denys D. [Etiopathogenesis of obsessive compulsive disorder]. In: Handboek Obsessieve-compulsieve stoornissen. De Tijdstroom; 2007.
39.Denys D. [Phenomenology of obsessive compulsive disorder]. In: Handboek Obsessieve-compulsieve stoornissen. De Tijdstroom; 2007.
40.Denys D. [The concept of obsessive compulsive spectrum disorders]. In: Handboek Obsessieve-compulsieve stoornissen. De Tijdstroom; 2007.
41.Denys D. [Genetics of obsessive compulsive disorder]. In: Handboek Obsessieve-compulsieve stoornissen. De Tijdstroom; 2007.
42.de Geus F, Denys D, Westenberg HG. Effects of quetiapine on cognitive functioning in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007;22:77-84.
43.de Bruijn C, Denys D. Predicting pharmacotherapy outcome from a retrospective chart study? J Clin Psychiatry. 2007;68:167; author reply 167-167; author reply 168.
44.Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG. Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry. 2007;68:747-753.
45.Denys D. How new is the new philosophy of psychiatry? Philos Ethics Humanit Med. 2007;2:22.
46.de Geus F, Denys DA, Sitskoorn MM, Westenberg HG. Attention and cognition in patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci. 2007;61:45-53.
47.de Bruijn C, Denys D. Post-traumatic stress disorder after life events. Br J Psychiatry. 2006;188:394-5; author reply 395. CV Damiaan Denys October 2010 8
48.Denys D. [Obsessive compulsive disorder: A terrible Uncertainty]. In: De grote Psychiatrie in klassieke teksten. De Tijdstroom; 2006.
49.Denys D, Van Nieuwerburgh F, Deforce D, Westenberg H. Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive-compulsive disorder in males. Eur Neuropsychopharmacol. 2006;16:446-450.
50.Vulink NC, Denys D, Bus L, Westenberg HG. Female hormones affect symptom severity in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2006;21:171-175.
51.Fineberg NA, Stein DJ, Premkumar P, et al. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol. 2006;21:337-343.
52.Vulink NC, Denys D, Bus L, Westenberg HG. Sexual pleasure in women with obsessive-compulsive disorder? J Affect Disord. 2006;91:19-25.
53.Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG. Association between serotonergic candidate genes and specific phenotypes of obsessive compulsive disorder. J Affect Disord. 2006;91:39-44.
54.Vulink NC, Sigurdsson V, Kon M, Bruijnzeel-Koomen CA, Westenberg HG, Denys D. [Body dysmorphic disorder in 3-8% of patients in outpatient dermatology and plastic surgery clinics]. Ned Tijdschr Geneeskd. 2006;150:97-100.
55.Stein DJ, Bolton D, Denys D, Huddle T, Powell T. Philosophy, Ethics, and Humanities in Medicine: expanding the open-access conversation on health care. Philos Ethics Humanit Med. 2006;1:E1.
56.Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am. 2006;29:553-84, xi.
57.van der Wee NJ, Hardeman HH, Ramsey NF, et al. Saccadic abnormalities in psychotropic-naive obsessive-compulsive disorder without co-morbidity. Psychol Med. 2006;36:1321-1326.
58.Denys D, Fluitman S, Kavelaars A, Heijnen C, Westenberg HG. Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive compulsive disorder. Psychoneuroendocrinology. 2006;31:355-360.
59.Denys D, de Geus F. Predictors of pharmacotherapy response in anxiety disorders. Curr Psychiatry Rep. 2005;7:252-257.
60.Denys D, de Geus F. Predictors of pharmacotherapy response in anxiety disorders. Curr Psychiatry Rep. 2005;7:252-257.
61.Vulink NC, Denys D, Westenberg HG. Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. J Clin Psychiatry. 2005;66:228-230.
62.Tenneij NH, van Megen HJ, Denys DA, Westenberg HG. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. J Clin Psychiatry. 2005;66:1169-1175.
63.Vulink N, Denys D. [Could you modify my nose?]. In: Probleem georienteerd denken in Psychiatrie. De Tijdstroom; 2005.
64.Vulink N, Denys D. [Body Dysmorphic disorder: A review]. Tijdschr Psychiatr. 2005;47:21-27.
65.De Geus F, Denys D. Pitfalls in factor analytic techniques. Am J Psychiatry. 2004;161:579-580. CV Damiaan Denys October 2010 9
66.van der Wee NJ, Stevens H, Hardeman JA, et al. Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am J Psychiatry. 2004;161:2201-2206.
67.Denys D, van der Wee N, Janssen J, De Geus F, Westenberg HG. Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry. 2004;55:1041-1045.
68.Van Megen H, Denys D. [Obsessive compulsive disorder]. In: Handboek Neurobiologische Psychiatrie . De Tijdstroom; 2004.
69.Denys D, Tenney N, van Megen HJ, de Geus F, Westenberg HG. Axis I and II comorbidity in a large sample of patients with obsessive-compulsive disorder. J Affect Disord. 2004;80:155-162.
70.Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry. 2004;65 Suppl 14:11-17.
71.Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry. 2004;65:37-43.
72.Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65:1040-1048.
73.Denys D. On Certainty: Studies in obsessive-compulsive disorder. In: PhD Thesis. ; 2004.
74.Denys D, de Geus F, van Megen HJ, Westenberg HG. Use of factor analysis to detect potential phenotypes in obsessive-compulsive disorder. Psychiatry Res. 2004;128:273-280.
75.Denys D, Fluitman S, Kavelaars A, Heijnen C, Westenberg H. Decreased TNF-alpha and NK activity in obsessive-compulsive disorder. Psychoneuroendocrinology. 2004;29:945-952.
76.Denys D, de Geus F, van Megen HJ, Westenberg HG. Symptom dimensions in obsessive-compulsive disorder: factor analysis on a clinician-rated scale and a self-report measure. Psychopathology. 2004;37:181-189.
77.Denys D, Klompmakers AA, Westenberg HG. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl). 2004;176:195-203.
78.Fluitman S, Denys D. PANDAS: A review. Tijdschr Psychiatr. 2004;46:755-761.
79.Tenney NH, Denys DA, van Megen HJ, Glas G, Westenberg HG. Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorder. Int Clin Psychopharmacol. 2003;18:29-33.
80.Denys D, Burger H, van Megen H, de Geus F, Westenberg H. A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2003;18:315-322.
81.Denys D, van der Wee N, van Megen HJ, Westenberg HG. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol. 2003;23:568-575.
82.Tenney NH, Schotte CK, Denys DA, van Megen HJ, Westenberg HG. Assessment of
CV Damiaan Denys October 2010 10
CV Damiaan Denys October 2010 11
DSM-IV personality disorders in obsessive-compulsive disorder: comparison of clinical diagnosis, self-report questionnaire, and semi-structured interview. J Pers Disord. 2003;17:550-561.
83.Denys D, van Megen HJ, Westenberg HG. Emerging skin-picking behaviour after serotonin reuptake inhibitor-treatment in patients with obsessive-compulsive disorder: possible mechanisms and implications for clinical care. J Psychopharmacol. 2003;17:127-129.
84.Denys D, Cath DC. [The inheritance of obsessive-compulsive disorders]. Ned Tijdschr Geneeskd. 2003;147:2166-2169.
85.van der Wee NJ, Ramsey NF, Jansma JM, et al. Spatial working memory deficits in obsessive compulsive disorder are associated with excessive engagement of the medial frontal cortex. Neuroimage. 2003;20:2271-2280.
86.Denys D. Reply to Clozapine and fluvoxamine together: More than two times alone. Tijdschr Psychiatr. 2003;45:409-411.
87.Denys D, Van Megen H, Westenberg H. The adequacy of pharmacotherapy in outpatients with obsessive-compulsive disorder. Int Clin Psychopharmacol. 2002;17:109-114.
88.Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry. 2002;63:700-703.
89.Denys D, Kavelaars A, Heijnen CJ, Westenberg H. A case of venlafaxine-induced inhibition of T-lymphocyte proliferation. Psychopharmacology (Berl). 2002;164:432.
90.Denys D, de Haan L. Reply to Neurotic excoriations and OCD. Tijdschr Psychiatr. 2002;44:409-411.
91.Denys D. [A phenomenology for Psychiatry] . De Uil van Minerva, Tijdschrift voor geschiedenis en wijsbegeerte van de cultuur. 2001;16:163-175.
92.Denys D, van Megen HJ, Westenberg HG. [Inadequate pharmacotherapy in patients with obsessive-compulsive disorder]. Ned Tijdschr Geneeskd. 2001;145:914-918.

Books
Damiaan Denys, Femke de Geus (Eds.), (2007). Handboek Obsessieve-compulsieve stoornissen, eerste druk. De Tijdstroom uitgeverij BV, Utrecht